LivaNova PLC (NASDAQ:LIVN) Receives $83.50 Consensus Price Target from Brokerages

Shares of LivaNova PLC (NASDAQ:LIVN) have been given an average recommendation of “Moderate Buy” by the eleven analysts that are currently covering the stock, MarketBeat.com reports. Five analysts have rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $83.50.

LIVN has been the topic of several research reports. Freedom Capital raised LivaNova to a “hold” rating in a report on Tuesday, June 30th. KeyCorp increased their price target on LivaNova from $83.00 to $92.00 and gave the company an “overweight” rating in a research note on Monday, June 22nd. Weiss Ratings upgraded LivaNova from a “hold (c)” rating to a “hold (c+)” rating in a report on Tuesday. Stifel Nicolaus set a $85.00 price objective on LivaNova in a research note on Wednesday, August 5th. Finally, Robert W. Baird reduced their price objective on LivaNova from $78.00 to $76.00 and set an “outperform” rating on the stock in a research note on Thursday, May 7th.

Insider Buying and Selling at LivaNova

In related news, Director Francesco Bianchi sold 1,800 shares of the firm’s stock in a transaction on Tuesday, May 26th. The shares were sold at an average price of $75.75, for a total value of $136,350.00. Following the completion of the transaction, the director directly owned 7,228 shares of the company’s stock, valued at approximately $547,521. This trade represents a 19.94% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Company insiders own 0.35% of the company’s stock.

Hedge Funds Weigh In On LivaNova

Several institutional investors have recently bought and sold shares of LIVN. Peregrine Capital Management LLC purchased a new stake in shares of LivaNova in the fourth quarter worth approximately $3,830,000. F m Investments LLC boosted its holdings in LivaNova by 46.9% during the 4th quarter. F m Investments LLC now owns 114,458 shares of the company’s stock valued at $7,043,000 after acquiring an additional 36,543 shares during the period. Vanguard Group Inc. boosted its holdings in LivaNova by 1.5% during the 4th quarter. Vanguard Group Inc. now owns 2,332,051 shares of the company’s stock valued at $143,491,000 after acquiring an additional 34,812 shares during the period. Hsbc Holdings PLC grew its position in LivaNova by 260.6% in the 4th quarter. Hsbc Holdings PLC now owns 20,301 shares of the company’s stock valued at $1,255,000 after acquiring an additional 14,671 shares during the last quarter. Finally, Rhenman & Partners Asset Management AB grew its position in LivaNova by 258.5% in the 4th quarter. Rhenman & Partners Asset Management AB now owns 190,000 shares of the company’s stock valued at $11,691,000 after acquiring an additional 137,000 shares during the last quarter. Institutional investors own 97.64% of the company’s stock.

LivaNova Trading Up 0.7%

LivaNova stock opened at $78.74 on Thursday. LivaNova has a 1 year low of $48.82 and a 1 year high of $85.76. The firm’s 50 day moving average price is $80.55 and its 200-day moving average price is $71.88. The company has a debt-to-equity ratio of 0.22, a current ratio of 1.45 and a quick ratio of 1.21. The stock has a market cap of $4.34 billion, a P/E ratio of 23.30 and a beta of 0.86.

LivaNova (NASDAQ:LIVN) last issued its earnings results on Thursday, August 6th. The company reported $1.26 earnings per share for the quarter, topping analysts’ consensus estimates of $1.09 by $0.17. The firm had revenue of $390.59 million during the quarter, compared to analyst estimates of $380.50 million. LivaNova had a net margin of 12.82% and a return on equity of 16.35%. LivaNova’s revenue for the quarter was up 10.8% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.05 earnings per share. On average, equities analysts predict that LivaNova will post 3.77 earnings per share for the current fiscal year.

About LivaNova

LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company’s primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.

The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.